All In Biotech

Drug Trial Radar · NCT06090422

Ketamine for Combined Depression and Alcohol Use Disorder

Ketamine for Combined Depression and Alcohol Use Disorder: A Blinded Randomized Active Placebo-controlled Trial (the KeDA Trial)

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

34

Planned (sponsor's estimate)

Start

Jan 20, 2025

Primary completion

Jul 1, 2028

Study completion Jul 1, 2028

Sponsor

Lead sponsor
University Hospital of North NorwayAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Exeter; Ostfold Hospital Trust
First posted
Oct 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to investigate the effects of ketamine, in combination with standard inpatient addiction therapy, for adults with depression and alcohol use disorder. After screening and enrollment, participants will undergo baseline assessments of depression, measures of alcohol use and craving, as well as neurocognitive function. Participants will then be randomized to either ketamine (intervention) or midazolam (control). All participants will be admitted for standard inpatient addiction therapy while receiving ketamine or midazolam. Measures on safety, depression and alcohol use disorder will be repeatedly assessed during and after treatment. Final follow-up assessment is scheduled 6 months after baseline assessment.

Conditions

  • Depression
  • Alcohol Use Disorder

Interventions

  • Ketamine HydrochlorideDrug

    Four single-doses, given two times per week for two weeks Dose: 0,8 mg/kg body weight Route of administration: intravenous infusions over 40 minutes

  • Midazolam HydrochlorideDrug

    Four single-doses, given two times per week for two weeks Dose: 0,02 mg/kg body weight Route of administration: intravenous infusions over 40 minutes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DepressionTime frame: Within 3 days after final treatment session

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Addiction Treatment, ØHT

    Moss, Norway · Not yet recruiting

  • Department of Addiction, University Hospital of North Norway

    Tromsø, Norway · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.